

National Institute on Drug Abuse

RESE

MONOGRAPH

15-NOV-1995 BLDSC BOSTON SPA
NIDA RESEARCH MONOGRAPH LS23 7BQ



6110.170000
AC 14

VOL 141

*ETOC

PB


1/1

**Problems of Drug
Dependence, 1993:
Proceedings of the
55th Annual Scientific
Meeting
The College on Problems
of Drug Dependence, Inc.
Volume II**

LOAN BAN

EXPIRES

15 MAY 1995



141



U.S. Department of Health and Human Services • Public Health Service • NATIONAL INSTITUTES OF HEALTH

Problems of Drug Dependence, 1993:

**Proceedings of the 55th Annual
Scientific Meeting, The College on
Problems of Drug Dependence, Inc.**

Volume II: Abstracts

Editor:

Louis S. Harris, Ph.D.

**NIDA Research Monograph 141
1994**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health**

**National Institute on Drug Abuse
5600 Fishers Lane
Rockville, MD 20857**

SAFETY AND PHARMACOKINETICS OF A NEW FORMULATION OF DEPOT NALTREXONE

S. J. Heishman, A. Francis-Wood, R. M. Keenan, C. N. Chiang, J. B. Terrill, B. Tai, and J. E. Henningfield

Naltrexone hydrochloride (Trexan) is an opioid antagonist, devoid of agonist activity, indicated in the maintenance of an opioid-free state in detoxified formerly opioid-dependent individuals. Typically, individuals are dosed with 50-150 mg of oral naltrexone every 24-72 hours. A major constraint on its utility as a treatment modality has been the lack of acceptance by clients, due in part to the frequency of dosing and incidence of adverse side effects.

The development of a depot formulation providing long-term opioid receptor blockade via sustained release of low levels of naltrexone may avoid these problems and thus improve treatment compliance. The purpose of this study was to evaluate the safety, pharmacokinetic, and pharmacodynamic profile of a newly developed form of depot naltrexone.

Four healthy nonsmokers, who reported no history of drug and alcohol dependence, participated in a placebo-controlled, double-blind, outpatient trial. On day one, subjects received two s.c. injections simultaneously, one in each upper arm (triceps area). Injections contained either naltrexone (52 mg) or placebo microcapsules. An assessment battery, consisting of dermatological, physiologic, subjective, and performance measures and blood samples for hematology, chemistry, and naltrexone concentration, was completed at pre-injection baseline and repeated at 4 and 8 hours postdrug and on days 2, 3, 5, 8, 11, 15, 22, 29, 36, 50, and 64.

Results indicated no tissue irritation or infection at the injection sites, and no adverse physical signs and symptoms. Laboratory results were normal. Mean maximal plasma naltrexone concentration of 0.93 ng/ml was observed at 24 hours post-naltrexone. Plasma levels declined to about 0.4 ng/ml at four days post-naltrexone and remained relatively stable through day 21.

Because the data suggest that this low dose (52 mg) of depot naltrexone is safe, testing will be conducted with higher doses to achieve a sustained naltrexone plasma concentration of 1-2 ng/ml.

AFFILIATIONS

Clinical Pharmacology Branch, Addiction Research Center, NIDA, NIH, Baltimore, MD and Medications Development Division, NIDA, NIH, Rockville, MD